Adimab Inks Merck, Roche Deals and Banks on the Value of Discovery

Adimab, the yeast-based antibody discovery biotech, has signed its first two alliances. In doing so the company revealed to Start-Up its partnering strategy, and discussed why it won't take a single step down the value chain into drug development. Can Adimab make discovery-only work where others have failed?